Compare OGC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGC | ERAS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.3B |
| IPO Year | 2010 | 2021 |
| Metric | OGC | ERAS |
|---|---|---|
| Price | $26.03 | $15.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 462.3K | ★ 4.7M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $43.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.90 | $2.71 |
| 52 Week High | $31.90 | $24.28 |
| Indicator | OGC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 50.15 |
| Support Level | $25.58 | $13.18 |
| Resistance Level | $27.09 | $15.71 |
| Average True Range (ATR) | 0.95 | 1.23 |
| MACD | 0.17 | 0.15 |
| Stochastic Oscillator | 44.01 | 46.34 |
OceanaGold Corp is a growing intermediate gold and copper producer committed to safely and responsibly maximizing the generation of Free Cash Flow from its operations and delivering robust returns for its shareholders. It has a portfolio of four operating mines: the Haile Gold Mine in the United States of America; the Didipio Mine in the Philippines; and the Macraes and Waihi operations in New Zealand. The company generates key revenue from Haile mines.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.